Position in AMRN
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$771,001
+$492,560 QoQ
Shares Held
48,369
+151.2% QoQ
Ownership
0.229%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#13
of 81 holders
Holding Since
Mar 2020
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AMRN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026RENAISSANCE TECHNOLOGIES LLC holds $598,181,374 across 8 Drug Manufacturers - General names. AMRN ranks #6 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
2,217,376 | $280,143,283 | |
| 2 | NVO |
Novo Nordisk A S
|
3,032,421 | $145,374,262 | |
| 3 | NVS |
Novartis AG
|
788,033 | $123,500,531 | |
| 4 | LLY |
ELI LILLY & Co
|
26,091 | $31,294,330 | |
| 5 | BIIB |
Biogen Inc.
|
77,744 | $16,797,368 | |
| 6 | AMRN |
Amarin Corp Plc\Uk
This page
|
48,369 | $771,001 | |
| 7 | SCLX |
Scilex Holding Co
|
33,064 | $257,899 | |
| 8 | NSRX |
Nasus Pharma Ltd
|
12,200 | $42,700 |
All Filings in AMRN
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $771,001 | 48,369 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $278,441 | 19,256 | Shares | Sole | 2026-05-14 | |
| 2023-06-30 | $64,141 | 53,900 | Shares | Sole | 2023-08-11 | |
| 2023-03-31 | $115,050 | 76,700 | Shares | Sole | 2023-05-12 | |
| 2021-06-30 | $6,188,940 | 1,413,000 | Shares | Sole | 2021-08-13 | |
| 2021-03-31 | $12,001,446 | 1,932,600 | Shares | Sole | 2021-05-13 | |
| 2020-12-31 | $14,251,993 | 2,914,518 | Shares | Sole | 2021-02-10 | |
| 2020-09-30 | $10,781,725 | 2,560,980 | Shares | Sole | 2020-11-13 | |
| 2020-06-30 | $26,387,766 | 3,813,261 | Shares | Sole | 2020-08-13 | |
| 2020-03-31 | $9,456,004 | 2,364,001 | Shares | Sole | 2020-05-14 | |
| No filing history on record for this holder in this stock. | ||||||